Organization
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School
22 abstracts
1 poster
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.Org: Gwangju Institute of Science and Technology (GIST), prismCDX Co., Ltd, Asan Institute for Life Sciences, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.Org: School of Biotechnology, Medical Oncology Department, CCRT/The Caroline Foundation, Galway University Hospital, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery.Org: Harvard Medical School, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Massachusetts General Hospital, Mass Eye and Ear/Mass Gen Hospital, Harvard University,
Abstract
Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes.Org: The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.Org: Labcorp Oncology, OmniSeq Inc. (Labcorp), Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute,
Abstract
Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.Org: Labcorp Oncology, Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Detection of TROP2: Ushering in a new choice in the treatment of patients with special types of invasive breast cancer.Org: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, The Fourth Hospital of Hebei Medical University, Shijiazhuang Yiling Pharmaceutical, China National Biotec Group,
Abstract
Clinical outcomes of patients with HER2-positive microinvasive breast cancer.Org: Department of Oncology, National Taiwan University Hospital, Asan Medical Center, University of Ulsan College of Medicine, Division of Breast Surgery, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.Org: Kyungpook National University Hospital, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV, Kyungpook National University School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital,
Abstract
Prospective evaluation of the breast microbiome and tumor microenvironment-related biomarkers of response to neoadjuvant systemic therapy in triple negative breast cancer.Org: Cancer Research @UCC, CUH/UCC Cancer Centre, HRB Clinical Research Facility, School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute,
Abstract
NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).Org: University of Kansas Medical Center, ZAS Hospitals, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, University of Kansas Cancer Center,
Abstract
Safety and efficacy of CyberKnife radiosurgery plus anlotinib hydrochloride in patients with recurrent glioblastoma: A prospective phase II single-arm study.Org: CyberKnife Center, Department of Neurosurgery, Prince of Wales Hospital, Huashan Hospital, Shanghai Medical College, Fudan University, Fudan University Shanghai Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Development of a multiparametric prognostic score based on PAM50, in patients with HR+/HER2- advanced breast cancer (aBC) treated with endocrine therapy (ET) plus cyclin dependent kinase 4 and 6 inhibitors (CDKi), within the CDK-PREDICT (SOLTI-1801) study and HCB cohort.Org: SOLTI Cancer Research Group, August Pi i Sunyer Biomedical Research Institute, Hospital Clínic de Barcelona, IDIBAPS, Biomedical Research Institute INCLIVA, Hospital Universitario 12 de Octubre Research Institute,